BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 24795056)

  • 1. Analysis of the Ten-Eleven Translocation 2 (TET2) gene mutation in myeloproliferative neoplasms.
    Ha JS; Jeon DS; Kim JR; Ryoo NH; Suh JS
    Ann Clin Lab Sci; 2014; 44(2):173-9. PubMed ID: 24795056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis.
    Tefferi A; Pardanani A; Lim KH; Abdel-Wahab O; Lasho TL; Patel J; Gangat N; Finke CM; Schwager S; Mullally A; Li CY; Hanson CA; Mesa R; Bernard O; Delhommeau F; Vainchenker W; Gilliland DG; Levine RL
    Leukemia; 2009 May; 23(5):905-11. PubMed ID: 19262601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlations between Janus kinase 2 V617F allele burdens and clinicohematologic parameters in myeloproliferative neoplasms.
    Ha JS; Kim YK; Jung SI; Jung HR; Chung IS
    Ann Lab Med; 2012 Nov; 32(6):385-91. PubMed ID: 23130336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms.
    Saint-Martin C; Leroy G; Delhommeau F; Panelatti G; Dupont S; James C; Plo I; Bordessoule D; Chomienne C; Delannoy A; Devidas A; Gardembas-Pain M; Isnard F; Plumelle Y; Bernard O; Vainchenker W; Najman A; Bellanné-Chantelot C;
    Blood; 2009 Aug; 114(8):1628-32. PubMed ID: 19564637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A TET2 rs3733609 C/T genotype is associated with predisposition to the myeloproliferative neoplasms harboring JAK2(V617F) and confers a proliferative potential on erythroid lineages.
    Shen XH; Sun NN; Yin YF; Liu SF; Liu XL; Peng HL; Dai CW; Xu YX; Deng MY; Luo YY; Zheng WL; Zhang GS
    Oncotarget; 2016 Feb; 7(8):9550-60. PubMed ID: 26843622
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Sassi H; Menif S; Ammar SB; Farrah A; Othmen HBH; Amouri H
    Pan Afr Med J; 2021; 39():194. PubMed ID: 34603575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL; Marton E; Plander M
    Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
    Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
    Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. JAK2-V617F-mutated myeloproliferative neoplasms reveal different allele burden within hematopoietic cell lineages: a microdissection study of bone marrow trephine biopsies.
    Kreft A; Kindler T; Springer E; Kirkpatrick CJ
    Virchows Arch; 2011 Nov; 459(5):521-7. PubMed ID: 22006129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
    Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
    Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
    Vytrva N; Stacher E; Regitnig P; Zinke-Cerwenka W; Hojas S; Hubmann E; Porwit A; Bjorkholm M; Hoefler G; Beham-Schmid C
    Arch Pathol Lab Med; 2014 Sep; 138(9):1203-9. PubMed ID: 25171702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JAK2-v617F mutation is associated with clinical and laboratory features of myeloproliferative neoplasms.
    Duletić AN; Dekanić A; Hadzisejdić I; Kusen I; Matusan-Ilijas K; Grohovac D; Grahovac B; Jonjić N
    Coll Antropol; 2012 Sep; 36(3):859-65. PubMed ID: 23213945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombosis among 1537 patients with JAK2
    Zhang Y; Zhou Y; Wang Y; Teng G; Li D; Wang Y; Du C; Chen Y; Zhang H; Li Y; Fu L; Chen K; Bai J
    Cancer Med; 2020 Mar; 9(6):2096-2105. PubMed ID: 31994332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ; Berneman Z; Schroyens W; De Raeve H
    Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype.
    Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
    Eur J Haematol; 2007 Dec; 79(6):508-15. PubMed ID: 17961178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Polymorphisms in LNK Gene Correlated to the Clinical Type of Myeloproliferative Neoplasms.
    Chen Y; Fang F; Hu Y; Liu Q; Bu D; Tan M; Wu L; Zhu P
    PLoS One; 2016; 11(4):e0154183. PubMed ID: 27111338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Different expression patterns of LGALS1 and LGALS3 in polycythemia vera, essential thrombocythemia and primary myelofibrosis.
    Moura LG; Tognon R; Nunes NS; Rodrigues LC; Ferreira AF; Kashima S; Covas DT; Santana M; Souto EX; Perobelli L; Simões BP; Dias-Baruffi M; Castro FA
    J Clin Pathol; 2016 Oct; 69(10):926-9. PubMed ID: 27402956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of mutation order on myeloproliferative neoplasms.
    Ortmann CA; Kent DG; Nangalia J; Silber Y; Wedge DC; Grinfeld J; Baxter EJ; Massie CE; Papaemmanuil E; Menon S; Godfrey AL; Dimitropoulou D; Guglielmelli P; Bellosillo B; Besses C; Döhner K; Harrison CN; Vassiliou GS; Vannucchi A; Campbell PJ; Green AR
    N Engl J Med; 2015 Feb; 372(7):601-612. PubMed ID: 25671252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contributions of bone marrow monocytes/macrophages in myeloproliferative neoplasms with JAK2
    Fan W; Cao W; Shi J; Gao F; Wang M; Xu L; Wang F; Li Y; Guo R; Bian Z; Li W; Jiang Z; Ma W
    Ann Hematol; 2023 Jul; 102(7):1745-1759. PubMed ID: 37233774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the Mutational Profiles of Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocytosis.
    Song J; Hussaini M; Zhang H; Shao H; Qin D; Zhang X; Ma Z; Hussnain Naqvi SM; Zhang L; Moscinski LC
    Am J Clin Pathol; 2017 May; 147(5):444-452. PubMed ID: 28419183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.